Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Executive Summary
Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.
You may also be interested in...
Vertex Plays Defense In CF With Concert Deal
Vertex is spending $160m to acquire Concert's "enhanced" version of its own blockbuster cystic fibrosis treatment Kalydeco, known as CTP-656, in a defensive move that could allow the company to simplify its dosing regimens and differentiate its products against future competition.
Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.